We’ve gotta hand it to GSK for taking the high road on physician payments for as long as they did. In 2013, after paying billions in fines to the Chinese and US governments in payments scandals, GSK figured it would be a good PR move to enforce a blanket ban on any payments to HCPs. But you know how the saying goes, nice guys finish last. Other major drugmakers didn’t follow GSK’s lead, leaving the company at a competitive disadvantage. So they’re getting rid of the blanket ban and making it more like a Snuggie ban—you know, with some holes to let them move around more easily. The company will resume payments in some restricted situations, like global experts speaking about their products, but well-below 2013 payment levels.